Divi’s Labs Delivers An In-Line Q3, Growth Outlook Intact: Dolat Capital 
Capsules are laid out for inspection on the production line of a drug factory. (Photographer: Tomohiro Ohsumi/Bloomberg)

Divi’s Labs Delivers An In-Line Q3, Growth Outlook Intact: Dolat Capital 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Divi’s Laboratories Ltd. reported an in-line Q3 driven by volume growth across the product portfolio.

While on a sequential basis the growth has come off a bit due to second wave lockdown in Europe, management remains confident of a robust FY22 driven by planned capex.

De-bottlenecking of units, backward integration, efficient technologies (implementation of greener chemistry) led to gross margin expansion at 69%, although management indicated nine months gross margin of 66-67% is sustainable as raw material costs of few key starting materials have risen.

Further, management is also confident of Ebitda margin expansion on a YoY basis despite incremental costs from newly commissioned capacities.

Click on the attachment to read the full report:

Dolat Capital Divis Laboratories Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.